Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC

SIMPLE SUMMARY: Most patients with EGFR-mutated NSCLC who receive treatment with targeted therapy will eventually develop resistance, meaning the therapy will lose its efficacy. Prior studies have shown a benefit to continuing to treat patients on TKI therapy despite limited progression of one or mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Novak, Jennifer, Salgia, Ravi, West, Howard, Villalona-Calero, Miguel A, Sampath, Sagus, Williams, Terence, Villaflor, Victoria, Massarelli, Erminia, Pathak, Ranjan, Koczywas, Marianna, Chau, Brittney, Amini, Arya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406789/
https://www.ncbi.nlm.nih.gov/pubmed/36010982
http://dx.doi.org/10.3390/cancers14163983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406789/
https://www.ncbi.nlm.nih.gov/pubmed/36010982
http://dx.doi.org/10.3390/cancers14163983

Ejemplares similares